Strategic partnership Leverage MetaVia's strong collaboration with Dong-A ST as a gateway to co-development opportunities, access to a robust R&D/CMS network, and potential joint initiatives in obesity and MASH programs.

Late-stage data momentum Capitalize on positive Phase 1 and early clinical data for DA-1726 and vanoglipel, highlighting weight loss and hepatoprotective signals to engage potential pharma partners, contract research organizations, and payer discussions for accelerated trials and market access strategies.

Obesity and MASH demand Target health systems, employers, and payers interested in obesity and metabolic disease pipelines; propose collaboration on real-world evidence, combination therapy strategies, and patient adherence programs to differentiate from GLP-1 rivals.

Clinical readiness Position MetaVia as a nimble, clinical-stage partner with ongoing Phase 1 Part 3/3a/3b titration; offer optioned pathways for co-funding, investigator-initiated studies, or regional expansion to accelerate development timelines.

Investment signals Use the established funding base and strong investor visibility to attract strategic investors or licensing partners seeking near-term value from obesity/metabolic assets, with clear milestones around topline data in Q4 2026.